GLP1s+ Summary In the last 30 years, weve gone from no GLP1s+ or truly scalable weight loss treatments to having treatments that: Efficacy: help patients lose 22% (and still rising) of their weight on average, up from 3-5% Disease Expansion: are approved for diabetes, obesity, cardiovascular disease and soon likely kidney disease and sleep apnea, with more conditions under study Frequency: are taken 1x/week, down from 2x/day (52 times per year versus 730) Form Factor: can be taken orally with more effective options on the horizon Improving the form factor, reducing the burden placed on the patient, all while maintaining and increasing efficacy across weight loss and other cardiometabolic measures, these are incredible feats of science that will benefit humanity in ways we cannot yet comprehend, especially once prices decline
Over time, they also begin to destroy specialized nerves in the brain
A systematic review of tens of animal-based studies indicated that Rhodiola improves learning and memory function in experimental models 33
Promising candidates that decrease TB burden Statins Statins, specifically simvastatin and rosuvastatin, are widely used to lower circulating cholesterol levels and prevent coronary heart disease
Biglycan: an emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance
In this context, PYC supplementation has been proposed to mitigate HCV-associated type 2 diabetes (Ezzikouri et al., 2016), although this hypothesis requires validation in clinical studies
